KOD
Kodiak Sciences Inc.
NASDAQ · Healthcare · Biotechnology · US
$35.36
−2.75%Aug 13, 2026, 00:00 UTC
Kodiak Sciences Inc. reported a net loss of $65.6 million, or $1.05 per diluted share, for Q2 2026, compared to a net loss of $54.3 million, or $1.03 per diluted share, in Q2 2025.
Source:Aug 11, 2026, 16:16 UTC
Kodiak Sciences initiated a global phase III clinical trial of KSI-501 for diabetic macular edema, evaluating a dual IL-6 and VEGF inhibitor approach.
Source:Jun 16, 2026, 16:09 UTC
Kodiak Sciences reported positive Phase 3 results for Zenkuda in diabetic retinopathy from the GLOW2 trial.
Source: